CereMark Pharma , a clinical-stage radiopharmaceutical company specializing in the development of novel Positron Emission Tomography (PET) imaging radiopharmaceuticals that bring highly precise ...

The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts say may be overblown.

Elsewhere, Fibrogen plans to lay off three-quarters of its U.S. staff, while gene editing specialist Intellia is now cleared to start a U.K. study focused on AAT deficiency.

Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.

Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.

The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.

The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.

The study is the latest test of a class of cholesterol medicines known as CETP inhibitors, which were abandoned by several large drugmakers last decade.

BALTIMORE, MD, July 30, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, and Zifo, the leading scientific informatics services company today announced a strategic partnership to ...

The collaboration between Lynx.MD and Schweiger Dermatology Group marks a significant leap forward in dermatological research, paving the way for meaningful improvements in patient care and treatment ...

The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.

The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.